Cite

HARVARD Citation

    Lassman, A. et al. (n.d.). Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-oncology. 17 (7), pp. 992-998. [Online]. 
  
Back to record